Ken Dobie, Founder & Principal, Skyemar Consulting

  Presentation Summary - An Effective Holistic Approach to Strategic Project Portfolio & Resource Management

Presentation Summary - An Effective Holistic Approach to Strategic Project Portfolio & Resource Management

An Effective Holistic Approach to Strategic Project Portfolio & Resource Management

Presentation Summary

Three to five-year new product road-maps are developed during an annual planning process and articulated in a document distributed to senior management and planning teams. Priorities for the coming year have resource forecasts integrated with the ongoing project portfolio to determine a balanced total resource supply and demand model. This model is reviewed on a quarterly basis with senior management to refine as timelines and priorities evolve. Monthly portfolio reviews provide more granular status summaries for ongoing projects in development and weekly pipeline phase gate reviews manage the pipeline as projects approach development milestones. The project portfolio and associated resources can be managed in a centralized or decentralized fashion depending on organizational scale and complexity while the overall planning process is managed centrally.

 

BIO

Ken is the founder and principal of Skyemar Consulting specializing in Strategic Planning & Portfolio Management. We facilitate the development of strategic priorities and translation into near term goals in conjunction with senior management. Prior to Skyemar, Ken was the Director of Corporate Planning & Portfolio Management at Illumina from 2007 to 2016 where he led the development of the annual strategic, operating, and portfolio plans, as well as resource management across 200 projects and 1,500 resources. Previously he was Associate Director at Ionis Pharmaceuticals where he performed genomic analysis of targets for drug development and is an author on more than 400 patents. Ken conducted a postdoctoral fellowship at the Salk Institute, La Jolla and has published five papers in peer reviewed journals. Ken earned his B.Sc. with Honors in Genetics from the University of Glasgow, a Ph.D. in Molecular Biology from the University of Edinburgh, and an MBA in Strategy & Healthcare from the University of California San Diego.